BHC Stock Recent News

BHC LATEST HEADLINES

BHC Stock News Image - accesswire.com

LAVAL, QC / ACCESSWIRE / June 14, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global diversified pharmaceutical company enriching lives through a relentless drive to deliver better health outcomes, recently presented at two global healthcare conferences. Bausch Health's gastroenterology (GI) business, Salix Pharmaceuticals presented data from its Amiselimod clinical trials at Digestive Disease Week (DDW) 2024 during the IMIBD Late Breakers and Innovations in IBD session on May 19, 2024, in Washington, D.C.

accesswire.com 2024 Jun 14
BHC Stock News Image - seekingalpha.com

Bausch + Lomb (BLCO) is a company with entrenched brands but poor recent financial performance. The company issued debt to acquire Dry Eye Disease [DED] drug Xiidra, hoping to ramp revenue to a more sensible level given their high fixed costs. The acquisition is not going well. Despite deploying substantial marketing expenses, Xiidra's revenue is mediocre and declining.

seekingalpha.com 2024 May 24
BHC Stock News Image - seekingalpha.com

Bausch + Lomb, a spin-off from Bausch Health, has shown solid performance with revenues of $4.1bn in 2023 and a narrowing net loss of $(260m). The company's Q1 2024 report shows growth in all segments, including Vision Care, Surgical, and Pharmaceuticals. Bausch + Lomb's CEO, the veteran Pharma dealmaker Brent Saunders, has praised the performance of the existing business and hinted at a focus on existing products and targeting growth.

seekingalpha.com 2024 May 22
BHC Stock News Image - accesswire.com

LAVAL, QC / ACCESSWIRE / May 17, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals, today announced that they will be presenting data from its Phase 2 trial evaluating Amiselimod as treatment for active ulcerative colitis (UC). The data will be presented at Digestive Disease Week (DDW) 2024 during the IMIBD Late Breakers and Innovations in IBD session on Sunday, May 19, 2024, in Washington, D.C.

accesswire.com 2024 May 17
BHC Stock News Image - Zacks Investment Research

Bausch's (BHC) first-quarter earnings and sales miss their respective estimates. Its shares fall in response to the results.

Zacks Investment Research 2024 May 03
BHC Stock News Image - Seeking Alpha

Bausch Health Companies [BHC] Q1 2024 Earnings Conference Call May 2, 2024 8:00 AM ET Company Participants Thomas Appio - CEO John Barresi - Interim CFO Garen Sarafian - IR Conference Call Participants Glen Santangelo - Jefferies Michael Nedelcovych - TD Cowen Douglas Miehm - RBC Capital Markets Umer Raffat - Evercore ISI Chi Fong - Bank of America David Amsellem - Piper Sandler Les Sulewski - Truist Securities Operator Greetings. Welcome to the Bausch Health first quarter 2024 earnings call.

Seeking Alpha 2024 May 02
BHC Stock News Image - Zacks Investment Research

Bausch Health (BHC) came out with quarterly earnings of $0.59 per share, missing the Zacks Consensus Estimate of $0.75 per share. This compares to earnings of $0.52 per share a year ago.

Zacks Investment Research 2024 May 02
BHC Stock News Image - Zacks Investment Research

Bausch (BHC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research 2024 Apr 29
BHC Stock News Image - Accesswire

LAVAL, QC / ACCESSWIRE / April 11, 2024 / Bausch Health Companies Inc. (NYSE:NHC)(TSX:BHC) will release first-quarter 2024 financial results on Thursday, May 2, 2024. Bausch Health will host a conference call and live webcast at 8:00 a.m.

Accesswire 2024 Apr 11
BHC Stock News Image - Zacks Investment Research

Bausch (BHC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Investment Research 2024 Apr 11
10 of 50